Research-driven botanical formulations to be available soon on OneLavi as Carmed continues U.S. expansion. The post Carmed Pharmaceuticals Expands U.S.Research-driven botanical formulations to be available soon on OneLavi as Carmed continues U.S. expansion. The post Carmed Pharmaceuticals Expands U.S.

Carmed Pharmaceuticals Expands U.S. Distribution with Upcoming Launch on OneLavi

2026/04/15 17:00
4 min read
For feedback or concerns regarding this content, please contact us at [email protected]
Boca Raton, Florida (Newsworthy.ai) Wednesday Apr 15, 2026 @ 5:00 AM Eastern —

Carmed Pharmaceuticals, a Turkey-based, science-driven company specializing in standardized carvacrol-based formulations, announced plans to expand its U.S. distribution with an upcoming launch on OneLavi, a curated online marketplace for beauty, health, and wellness products.

The planned launch represents another step in Carmed’s U.S. expansion strategy, focused on increasing accessibility to its research-driven formulations while building long-term credibility in the American market.  The OneLavi launch follows Carmed’s previously announced plans to introduce its formulations on Amazon, reflecting a broader multi-channel approach to U.S. distribution.

Carmed’s approach integrates traditional botanical knowledge with modern pharmaceutical methodology to develop standardized formulations designed to support immune resilience, cellular health, and overall physiological balance.

Expanding Through Curated Digital Retail

The addition of OneLavi to Carmed’s distribution strategy reflects the company’s focus on reaching consumers through curated platforms that emphasize quality, transparency, and product discovery.

Unlike broader marketplaces, OneLavi provides a more selective environment where brands are positioned alongside premium wellness offerings, allowing Carmed to introduce its formulations within a more focused consumer experience.

“Expanding onto OneLavi allows us to introduce our formulations in a curated environment where quality and product integrity are prioritized,” said Mustafa Can, Founder of Carmed Pharmaceuticals. “This aligns with our commitment to standardized development and consistent formulation quality.”

Product Portfolio Coming to OneLavi

As part of its OneLavi launch, Carmed Pharmaceuticals plans to introduce several of its core formulations:

  • Vacrol® Kids Spray – A carvacrol-based spray formulated to support upper respiratory wellness and microbial balance for children ages 4-11.

  • S-Mix® – A synergy-driven formulation designed to support immune function and healthy cellular activity.

  • Vacrol® Capsule – A standardized carvacrol formulation developed to support microbial balance and immune resilience.

  • Vacrol-M® Capsule – A multi-component botanical formulation designed to support immune function and respiratory wellness.

  • Omevaq-3® – A targeted formulation developed to support cellular energy metabolism and cognitive wellness.

Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified.

According to the company, all formulations are developed using standardized processes designed to ensure consistency, reproducibility, and quality control across production.

Research-Driven Development and Scientific Collaboration

Carmed’s formulation approach is supported by ongoing collaboration with academic institutions, laboratories, and medical researchers focused on bioactive compounds and formulation science.

In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models, contributing to the broader scientific investigation of carvacrol-based formulations and multicomponent botanical interactions.

The company emphasizes that this research reflects scientific investigation into formulation science and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

Strengthening U.S. Market Presence

Carmed states that its U.S. strategy is centered on expanding availability across both large-scale and curated retail platforms while maintaining alignment with regulatory standards and long-term scientific positioning.

“The OneLavi launch is an important step in building awareness and accessibility for Carmed in the United States,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “We are focused on introducing our formulations to new audiences while maintaining the same standards of quality, consistency, and research-driven development.”

Availability timelines and product listings on OneLavi will be announced in the coming weeks.

About Carmed Pharmaceuticals

Carmed Pharmaceuticals is a research-driven company specializing in standardized, mechanism-based botanical formulations rooted in Anatolia’s rich botanical heritage. Integrating traditional plant knowledge with modern pharmaceutical technology, Carmed focuses on analytical validation, quality control, and reproducible formulation design.

Officially established in 2019 following years of focused research and development, the company operates with nearly 15 years of industry experience. All products are manufactured in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards, emphasizing safe production, environmental awareness, and continuous quality improvement.

Carmed develops standardized formulations designed to support preventive wellness, immune resilience, and cellular health through science-informed, quality-controlled processes.

Visit Carmed Pharmaceuticals website and visit them on Instagram.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire – News Marketing Platform™. The reference URL for this press release is located here Carmed Pharmaceuticals Expands U.S. Distribution with Upcoming Launch on OneLavi.

The post Carmed Pharmaceuticals Expands U.S. Distribution with Upcoming Launch on OneLavi appeared first on citybuzz.

Market Opportunity
United Stables Logo
United Stables Price(U)
$0.9999
$0.9999$0.9999
+0.03%
USD
United Stables (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!